CNS Pharmaceuticals and WPD Pharmaceuticals Identify Leading Polish Medical Institutions for Berubicin Phase 2 Clinical Trial Apr 30, 2020 8:00am EDT
CNS Pharmaceuticals Announces Filing of FDA Orphan Drug Designation for Brain Cancer Drug Berubicin Apr 23, 2020 8:00am EDT
CNS Pharmaceuticals to Host Shareholder Webinar Today to Discuss Coronavirus Collaboration, the Significance of WP1244, and an Update on the Cancer Free Survivor Treated with Berubicin Apr 22, 2020 8:00am EDT
CNS Pharmaceuticals Announces Shareholder Webinar to Discuss Collaboration with WPD Pharmaceuticals for Developing Coronavirus Drug Candidates, the Significance of WP1244, and an Update on the Cancer Free Survivor Treated with Berubicin Apr 15, 2020 8:00am EDT
CNS Pharmaceuticals Announces Independent University Research Confirms Active Compound in WP1122 Completely Prevents Coronavirus Replication In Vitro; WP1122 is Subject to Development Agreement with WPD Pharmaceuticals Apr 13, 2020 8:00am EDT
